These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 23144908)

  • 1. Immunogenicity and acceptance of influenza A (H1N1) vaccine in a cohort of chronic hepatitis C patients receiving pegylated-interferon treatment.
    Hernández-Guerra M; González-Méndez Y; de Molina P; Gimeno-García AZ; Carrillo M; Casanova C; Pumarola T; Jimenez A; Hernández-Porto M; Torres A; Quintero E
    PLoS One; 2012; 7(11):e48610. PubMed ID: 23144908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of influenza A(H1N1)pdm09 vaccine and the associated factors on lowered immune response in patients with hepatitis C.
    Ohfuji S; Fukushima W; Tamori A; Maeda K; Maeda A; Hirota Y
    Influenza Other Respir Viruses; 2013 May; 7(3):456-65. PubMed ID: 22897938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serological response to the 2009 H1N1 influenza vaccination in patients with inflammatory bowel disease.
    Cullen G; Bader C; Korzenik JR; Sands BE
    Gut; 2012 Mar; 61(3):385-91. PubMed ID: 21757451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pandemic whole-virion, Vero-cell-derived, adjuvant-free influenza A H1N1 vaccine in patients with solid tumors and hematologic malignancies receiving concurrent anticancer treatment: Immunogenicity, tolerability, and acceptability during the pandemic situation.
    Lagler H; Tobudic S; Ramharter M; Elandt K; Sperr WR; Redlberger-Fritz M; Popow-Kraupp T; Jäger U; Zielinski CC; Burgmann H
    Vaccine; 2012 Nov; 30(48):6864-70. PubMed ID: 22989690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
    Ehrlich HJ; Müller M; Kollaritsch H; Pinl F; Schmitt B; Zeitlinger M; Loew-Baselli A; Kreil TR; Kistner O; Portsmouth D; Fritsch S; Maritsch F; Aichinger G; Pavlova BG; Barrett PN
    Vaccine; 2012 Jun; 30(30):4543-51. PubMed ID: 22475864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response to 2009 pandemic influenza A (H1N1) vaccine in HIV-infected patients and the influence of prior seasonal influenza vaccination.
    Soonawala D; Rimmelzwaan GF; Gelinck LB; Visser LG; Kroon FP
    PLoS One; 2011 Jan; 6(1):e16496. PubMed ID: 21304982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The priming effect of previous natural pandemic H1N1 infection on the immunogenicity to subsequent 2010-2011 influenza vaccination in children: a prospective cohort study.
    Kang EK; Eun BW; Kim NH; Lim JS; Lee JA; Kim DH
    BMC Infect Dis; 2016 Aug; 16(1):438. PubMed ID: 27549626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intradermally-administered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age.
    Gorse GJ; Falsey AR; Fling JA; Poling TL; Strout CB; Tsang PH
    Vaccine; 2013 May; 31(19):2358-65. PubMed ID: 23499604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of a 2009 influenza A (H1N1) vaccine in hemodialysis patients.
    Lertdumrongluk P; Changsirikulchai S; Limkunakul C; Prachukthum P; Punpiput P; Buppanharun R; Chotpitayasunondh C
    Vaccine; 2012 Feb; 30(6):1108-14. PubMed ID: 22178515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influenza Vaccine-Induced Antibody Responses Are Not Impaired by Frailty in the Community-Dwelling Elderly With Natural Influenza Exposure.
    Narang V; Lu Y; Tan C; Camous XFN; Nyunt SZ; Carre C; Mok EWH; Wong G; Maurer-Stroh S; Abel B; Burdin N; Poidinger M; Tambyah PA; Bosco N; Visan L; Ng TP; Larbi A
    Front Immunol; 2018; 9():2465. PubMed ID: 30405641
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children.
    Knuf M; Leroux-Roels G; Rümke H; Rivera L; Pedotti P; Arora AK; Lattanzi M; Kieninger D; Cioppa GD
    Hum Vaccin Immunother; 2015; 11(2):358-76. PubMed ID: 25621884
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term immunogenicity of the pandemic influenza A/H1N1 2009 vaccine among health care workers: influence of prior seasonal influenza vaccination.
    Song JY; Cheong HJ; Seo YB; Kim IS; Noh JY; Choi WS; Lee J; Jeong HW; Kee SY; Kim WJ
    Clin Vaccine Immunol; 2013 Apr; 20(4):513-6. PubMed ID: 23365206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serological response to influenza A H1N1 vaccine (Pandemrix®) and seasonal influenza vaccine 2009/2010 in renal transplant recipients and in hemodialysis patients.
    Ott U; Sauerbrei A; Lange J; Schäfler A; Walther M; Wolf G; Wutzler P; Zell R; Krumbholz A
    Med Microbiol Immunol; 2012 Aug; 201(3):297-302. PubMed ID: 22350187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of a novel seasonal influenza preservative-free vaccine manufactured in Kazakhstan: Results of a randomized, comparative, phase II clinical trial in adults.
    Sarsenbayeva G; Volgin Y; Kassenov M; Issagulov T; Bogdanov N; Sansyzbay A; Stukova M; Buzitskaya Z; Кulmagambetov I; Davlyatshin T; Khairullin B
    Hum Vaccin Immunother; 2018 Mar; 14(3):609-614. PubMed ID: 29112488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics of the antibody response to seasonal influenza vaccination among the elderly.
    Kositanont U; Assantachai P; Wasi C; Puthavathana P; Praditsuwan R
    Viral Immunol; 2012 Dec; 25(6):471-6. PubMed ID: 23061793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to a monovalent 2009 influenza A (H1N1) vaccine.
    Greenberg ME; Lai MH; Hartel GF; Wichems CH; Gittleson C; Bennet J; Dawson G; Hu W; Leggio C; Washington D; Basser RL
    N Engl J Med; 2009 Dec; 361(25):2405-13. PubMed ID: 19745216
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of inactivated monovalent 2009 H1N1 influenza A vaccine in immunocompromised children and young adults.
    Hakim H; Allison KJ; Van De Velde LA; Li Y; Flynn PM; McCullers JA
    Vaccine; 2012 Jan; 30(5):879-85. PubMed ID: 22155630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Similar immunogenicity of the A/H1N1 2009 pandemic influenza strain when used as a monovalent or a trivalent vaccine.
    Van der Vliet D; Pepin S; Lambert M; Fauchoux N; Donazzolo Y; Dupuy M; Dakowski C; Denis M
    Hum Vaccin; 2010 Oct; 6(10):823-8. PubMed ID: 20935517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pandemic influenza A H1N1 vaccine in recipients of solid organ transplants: immunogenicity and tolerability outcomes after vero cell derived, non-adjuvanted, whole-virion vaccination.
    Lagler H; Wenisch JM; Tobudic S; Gualdoni GA; Rödler S; Rasoul-Rockenschaub S; Jaksch P; Redlberger-Fritz M; Popow-Kraupp T; Burgmann H
    Vaccine; 2011 Sep; 29(40):6888-93. PubMed ID: 21803100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.